Policymakers often rely on impact and cost-effectiveness evaluations to inform decisions
about the introduction of health interventions in low-and middle-income countries (LMICs); …

Methods A review of the economic literature was undertaken to identify previously published
economic evidence regarding the cost-effectiveness of the use of RSV vaccinations for …

Aims To capture the economic and healthcare resource utilization (HCRU) burden in older
adults due to respiratory syncytial virus (RSV) infection. Methods An electronic literature …

Background Respiratory syncytial virus (RSV) frequently causes acute lower respiratory
infection in children under 5, representing a high burden in Gavi-eligible countries (mostly …

With the approval of the first vaccines against respiratory syncytial virus (RSV) and a novel
RSV‐neutralizing antibody, 2023 has been perceived as a game‐changing year in …

Background Respiratory syncytial virus (RSV) is a major cause of acute respiratory infection
(ARI), with high morbidity and mortality worldwide. RSV costing and burden estimates can …

Morbidity and mortality caused by respiratory syncytial virus (RSV) in older adults and those
with underlying health conditions can be potentially alleviated through vaccination. To assist …

Background New prevention strategies for respiratory syncytial virus (RSV) are emerging,
but it is unclear if they will be cost-effective in low-and middle-income countries. We …

Background Current estimates of the economic burden of respiratory syncytial virus (RSV)
are needed for policymakers to evaluate adult RSV vaccination strategies. Methods A cost-of …

Background Respiratory syncytial virus (RSV) is a leading cause of respiratory disease in
young children. A number of mathematical models have been used to assess the cost …